NEWDRU / ANNUAL
No resting orders on this market.
Resolves Yes if Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.